Weight changes before and after lurasidone treatment: a real-world analysis using electronic health records

Table 1 Patient demographic and clinical characteristics at index

Characteristics	Lurasidone (N = 439)
Age (years), mean (SD)	42.2 (13.5)
Female, N (%)	306 (69.7%)
Follow-up duration (days), mean (SD)	225.1 (124.6)
Diagnosis of schizophrenia or bipolar disorder, N (%)
Schizophrenia spectrum diagnosis	83 (18.9%)
Bipolar disorder diagnosis	206 (46.9%)
Other/unknown diagnosis^a	150 (34.2%)
Prior use of any second-generation antipsychotics N (%)	201 (45.8%)
Prior use of second-generation antipsychotics associated with medium or higher risk for weight gain^b	119 (27.1%)
Prior use of any first-generation antipsychotic, N (%)	62 (14.1%)
Prior use of other medications, N (%)
Antidepressants	246 (56.0%)
Diuretics	90 (20.5%)
Comorbidities, N (%)
Depression	196 (44.6%)
Substance abuse	166 (37.8%)
Hypertension	158 (36.0%)
Hyperlipidemia	155 (35.3%)
Diabetes	89 (20.3%)
Chronic obstructive pulmonary disease	85 (19.4%)
Charlson Comorbidity Index Score, mean (SD)	0.8 (1.3)
Weight^c and BMI classification^d
Weight (kg), mean (SD)	93.9 (25.4)
Underweight, N (%)	4 (0.9%)
Normal, N (%)	70 (15.9%)
Overweight, N (%)	89 (20.3%)
Obese, N (%)	276 (62.9%)

^aAs lurasidone would not be prescribed for any other condition except schizophrenia and bipolar, and the lack of a diagnosis in administrative data does not indicate the lack of the disorder, the data from these patients was deemed acceptable to use in the analysis
^bSecond-generation antipsychotics associated with medium or higher risk of weight gain included clozapine, olanzapine, quetiapine, and risperidone
^cWeight was the most recent weight observation at index (i.e., weight observation closest to and before index date)
^dBMI classification based on the closest BMI reading prior to the index date. Underweight, BMI < 18.5 kg/m²; normal weight, BMI ≥ 18.5 and < 25.0 kg/m²; overweight, BMI ≥ 25.0 and < 30 kg/m²; obese, BMI ≥ 30 kg/m²

ISSN: 1744-859X